Further analysis of a Phase II study of therapeutic HIV vaccine candidate Vacc-4x revealed a potential biomarker associated with participants who experienced a more profound viral load reduction after receiving the vaccine.
St George's, University of London is collaborating with Bionor Pharma to study HIV-associated immune activation that drives disease progression.
Based on St George's work within this field, Bionor Pharma has developed a peptide (C5/gp41732-744) that can be used to detect antibodies against a part of the HIV envelope glycoprotein.
Researchers found that median HIV viral load reduction more than doubled among participants with high anti-C5/gp41732-744 antibody levels who received the HIV vaccine candidate.
Also Read
Further study will be needed to confirm anti-C5/gp41732-744 antibody levels as a biomarker for improved response to Vacc-4x, researchers said.
"In spite of very effective drugs against HIV these need to be taken daily and have significant side-effects," said Professor Angus Dalgleish, of St George's, University of London.
"The ability to replace this daily medication with a vaccine that allows several months of being off medication, not to mention the enormous financial gains that would be delivered to health services, is a step closer with these preliminary results," Dalgleish said.